From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung - BiotechTV - News | Lyssna här | Poddtoppen.se
Fler avsnitt av From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system
2026-10-19 |
13 min
+
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
2026-10-15 |
11 min
+
At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
2026-10-14 |
19 min
+
Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more
2026-10-07 |
23 min
+
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
2026-10-06 |
27 min
+
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
2026-10-02 |
20 min
+
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
2026-09-29 |
7 min
+
From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
2026-09-28 |
9 min
+
From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
2026-09-28 |
13 min
+
Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study
2026-09-21 |
9 min
+
Podden och tillhörande omslagsbild på den här sidan tillhör
BiotechTV. Innehållet i podden är skapat av BiotechTV och inte av,
eller tillsammans med, Poddtoppen.
En ny version av sidan finns tillgänglig.
Ladda om
Stäng
